In cancers with BRCA1/BRCA2 mutations or other defects in HR repair, cells are dependent on poly-adenosyl-ribose polymerase (PARP) enzymes to carry repair of their damaged DNA and are thus prone to apoptosis if the enzyme is inhibited by PARP inhibitors, a concept known as synthetic lethality [30]. This evidence concerns the gene BRCA2 and cancer.